regulatory approval

Amazon's Zoox launches in Austin and Miami but still lacks federal approval to charge for rides despite 2M autonomous miles.

Hagens Berman investigates $QURE over FDA allegations of misrepresented gene therapy data and manipulated study design. Stock tumbled 49% following November 3 FDA rebuttal.

CVB Financial and Heritage Commerce shareholders approve merger; closing expected Q2 2026 pending regulatory approvals.

Vertex Pharmaceuticals trails broader market but boasts promising pipeline candidates in kidney disease and diabetes, positioning potential recovery.

Co-Diagnostics ships PCR instruments and TB test kits to India for clinical studies, aligned with new WHO recommendations for molecular testing using tongue swabs.

NuScale offers higher growth potential as the only approved SMR designer but faces years before revenue. Constellation Energy provides profitable operations, Microsoft/Meta contracts, and a growing dividend—making it the more prudent choice.

Mountain Commerce Bancorp receives Federal Reserve and Arkansas regulatory approvals for merger with Home BancShares, expected to close in early Q2 2026.

NuScale Power trades below $12 as a pre-commercial nuclear technology firm with $31.5M revenue but no operational reactors, betting on a $2.2T sector opportunity.

Estée Lauder shares fell 7.72% to $79.29 after announcing preliminary merger discussions with Spanish luxury giant Puig Brands. No final decision made; deal pending regulatory approval.

South Plains Financial and BOH Holdings receive final regulatory and shareholder approvals for merger, closing set for April 1, 2026.

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.

Valneva-Pfizer Lyme vaccine trial misses primary endpoint but shows 73-75% secondary efficacy; Pfizer to seek regulatory approval despite setback. Valneva shares fell 35.27%.

Senate Democrats demand FCC probe into foreign funding in $111B Paramount-Skydance-Warner Bros. Discovery deal, citing concerns over Chinese and Gulf state investor influence on CNN.

Sampo secures Swedish regulatory approval to expand internal capital model to Danish operations, unlocking €90 million capital relief starting Q1 2026.

NuScale Power stock has corrected 40% to $4B valuation, offering growth potential from AI's electricity demands but facing execution risks and intense competition.

Lawsuit alleges Trump promised Ellison Warner Bros deal. Paramount declared winning bidder; DOJ approval pending amid regulatory scrutiny.

Morris State Bancshares shareholders approve merger with Vallant Financial. Deal closes April 1, 2026, with special $0.54/share dividend approved.

Morris State Bancshares shareholders approve Vallant Financial merger with all regulatory approvals secured. Special dividend of $0.54 per share set for March 30, 2026.

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.

HSBC downgraded $LLY to Reduce, citing inflated obesity market projections. The analyst sees $80-120B market by 2032, not Wall Street's $150B estimate.